Sentia Medical Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sentia Medical Sciences is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach to chronic stress by developing astressins, peptide antagonists that block CRF receptors, aiming to re-establish biological homeostasis. Its pipeline targets significant unmet needs in gastrointestinal motility disorders like IBS, gastroparesis, and postoperative ileus, as well as endocrine conditions like Congenital Adrenal Hyperplasia. Sentia's core technology is exclusively licensed from the Salk Institute and is distinguished by its potential for long-acting effects and a favorable safety profile observed in preclinical models.

GastrointestinalEndocrineNeurology

Technology Platform

Platform of peptide antagonists (astressins) that block corticotropin-releasing factor (CRF) and urocortin receptors (CRF1/2) to modulate the body's central stress response system.

Opportunities

Sentia is pioneering a first-in-class approach to treating the root cause of numerous chronic diseases by targeting the central stress response.

Success in one indication, such as IBS or POI, could validate the platform and unlock massive adjacent markets in other stress-related gastrointestinal, endocrine, and psychiatric disorders.

The long-acting profile of its astressins could offer a significant competitive and patient compliance advantage if demonstrated in humans.

Risk Factors

The core scientific premise—that systemic CRF receptor blockade is safe and effective for chronic diseases—is high-risk and unproven in clinical settings.

As a preclinical company with a single platform, Sentia faces significant financing, development, and regulatory risks before generating any human proof-of-concept data.

Future competition from larger biopharma entities and the challenge of commercializing a novel disease-modifying stress therapeutic pose additional long-term risks.

Competitive Landscape

The competitive landscape for direct CRF receptor antagonists is relatively sparse, especially in gastroenterology, giving Sentia a potential first-mover advantage. However, it faces indirect competition from numerous companies developing symptomatic treatments for its target indications (e.g., IBS drugs, antiemetics). If its mechanism is validated, it may attract competition from well-capitalized pharmaceutical companies with greater development and commercialization resources.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →